Cocrystal Pharma receives FDA Fast Track designation for CDI-988

Cocrystal Pharma (COCP) announced that the FDA has granted Fast Track designation to its oral, direct-acting protease inhibitor, CDI-988, the first oral antiviral candidate being developed for treatment and prophylaxis of norovirus infection.